Fresenius Kabi announced the launch of Acetylcysteine Solution, 20% for inhalation or oral administration.

When administered as an inhalation, Acetylcysteine Solution is indicated in adjuvant therapy for patients with certain lung diseases including chronic and acute bronchopulmonary disease.   When administered orally, it is used to prevent or lessen hepatic injury following acetaminophen overdose.

Acetylcysteine Solution has been on the FDA and the American Society of Health-System Pharmacists (ASHP) drug shortage lists since 2011. This product launch should help mitigate the drug shortage for this product. Fresenius Kabi has a licensing agreement with InnoPharma to sell, market and distribute Acetylcysteine Solution, USP, in the United States.

Acetylcysteine Solution, 20% is available in 30mL vial for inhalation or oral administration.

For more information call (847) 969-2700 or visit